KIT and PDGFRα mutations in 104 patients with gastrointestinal stromal tumors (GISTs): A population-based study

Annals of Oncology

Volumn 19, Issue 4, 2008, Pages 706-710

  Braconi, Chiara ^a,f   Bracci, R ^a,b   Bearzi, I ^a   Bianchi, F ^a   Costagliola, A ^a   Catalani, R ^a   Mandolesi, A ^a   Ranaldi, R ^a   Galizia, E ^a   Cascinu, S ^b   Rossi, G ^c   Giustini, L ^d   Latini, L ^e   Valeri, N ^a,f   Cellerino, R ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c Ospedale Murri   (Italy)

^d Ospedale di Fermo   (Italy)

^e Ospedale di Macerata   (Italy)

^f OHIO STATE UNIVERSITY   (United States)

Author keywords

GISTs; KIT; Mutations; PDGFR ; Prognosis

Indexed keywords

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; GENE DUPLICATION; GENE INSERTION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; WILD TYPE; COMPARATIVE STUDY; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENE DUPLICATION; HUMANS; MALE; MIDDLE AGED; MITOTIC INDEX; POINT MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 41549165611     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm503     Document Type: Article

References (13)

1. Perez EA, Livingstone AS, Franceschi D et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 2006; 202: 623-629.
2. Lev S, Blechman J, Nishikawa S et al. Interspecies molecular chimeras of kit help define the binding site of the stem cell factor. Mol Cell Biol 1993; 13: 2224-2234.
3. Antonescu CR, Sommer G, Sarran L et al. Association of KIT axon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003; 9: 3329-3337.
4. Singer S, Rubin BP, Lux ML et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002; 20: 3898-3905.
5. Heinrich MC, Corless CL, Blanke CD et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24: 4764-4774.
6. Kim TW, Lee H, Kang YK et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004; 10: 3076-3081.
7. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-465.
8. De Matteo RP, Lewis JJ, Leung D et al. Two hundred gasttrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58.
9. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22: 3813-3825.
10. Tornillo L, Terracciano I.M. An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol 2006; 59: 557-563.
11. Martin J, Poveda A, Llombart-Bosch A et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patents with completely resected gastrointestinal stromal tumors: A study by the Spanish Group for Sarcoma Research (GEIS). J Clin Onco! 2005; 23: 6190-6198.
12. Lasota J, Wozniak A, Sarlomo-Rikala M et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000; 157: 1091-1095.
13. Debiec-Rychter M, Lasota J, Sarlomo-Rikama M et al. Chromosomal aberrations in malignant gastro-intestinal stromal tumors: Correlation with c-kit gene mutation. Cancer Genet Cytogenet 2001; 128: 24-30.